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Abstract 
 
Antibodies are known to have an important role in the development of rheumatoid arthritis (RA), 
one of the most prevalent chronic inflammatory diseases which primarily involves the joints. 
Most RA patients develop autoantibodies against immunoglobulin G (IgG) and changes in IgG 
glycosylation have been associated with RA. We undertook this study to determine whether 
altered IgG glycosylation precedes the disease diagnosis. We studied IgG glycosylation in RA in 
two prospective cohorts (N=14,749) by measuring 28 IgG glycan traits in 179 subjects who 
developed RA within 10-years follow-up and 358 matched controls.Ultra performance liquid 
chromatography method based on hydrophilic interactions (HILIC-UPLC) was used to analyse 
IgG glycans. Future RA diagnosis associated with traits related to lower galactosylation and 
sialylation of IgG when comparing the cases to the matched controls. In RA cases, these traits 
did not correlate with the time between being recruited to the study and being diagnosed with RA 
(median time 4.31 years). The difference in IgG glycosylation was relatively stable and present 
years before diagnosis. This indicates that long-acting factors affecting IgG glycome 
composition are among the underlying mechanisms of RA and that decreased galactosylation is a 
pre-existing risk factor involved in the disease development. 
 
Keywords: rheumatoid arthritis, immunoglobulin G, N-glycans, biomarker, risk factor 
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1. Introduction 
 
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease which primarily 
involves joints and has an incidence of 0.5 – 1%[1], making it one of the most prevalent chronic 
inflammatory diseases[2]. Even though mechanisms of the disease development are yet to be 
completely identified, antibodies are known to be important players in that processand connected 
with the disease severity[2–4].Autoantibodies against citrullinated peptides (ACPAs) and 
immunoglobulin G (IgG) are particularly important in the diagnostics of RA. An early diagnosis 
is central to the treatment of RA, as starting a therapy as soon as possible can prevent or halt 
joint damage in many patients[5].  
 IgG is the most abundant immunoglobulin in human circulation and a majority of RA 
patients produce autoantibodies binding to IgG, collectively denominated rheumatoid factor 
(RF). IgGitself is a glycoprotein and both its antigen binding region (Fab) as well as the fragment 
crystallizableregion(Fc) are known to be N-glycosylated[6]. These glycans are mostly 
biantennary complex-type N-glycans carryingvarying levels of a core fucose, N-
acetylglucosamine (GlcNAc), galactose and sialic acid[7]. Glycosylation of IgG has a major 
effect on its effector and antigen binding functions and may also affect its role in RA. 
IgG glycosylation changes are known to be associated with RA since 1985 when Parekh 
et al. showed that galactose and sialic acid levels were lower in patients with RA[8]. Moreover, 
these changes follow the disease remission during pregnancy[9–11]and an efficient therapy 
treatment[12–15] as well as relapses and progression of the disease[16]. Besides RA, N-
glycosylation is shown to be altered in other autoimmune diseases such as systemic lupus 
erythematosus[17] and inflammatory bowel disease[18] as well as in inflammatory diseases 
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without autoimmune character[19–21].Some authors have also suggested that there is a “sugar 
print” characteristic for RA which enables distinguishing it from different similar 
diseases[22,23]. Whether changes in IgG glycosylation contribute to RA development is unclear, 
although a recent Mendelian randomization study does not support a simple causal 
relationship[24]. 
Recent development of new analytical methods and approaches has enabled the analysis 
of IgG N-glycome in a larger number of patients and with higher accuracy[25,26]. Ultra 
performance liquid chromatography based on hydrophilic interactions (HILIC-UPLC) analysis 
of 2-aminobenzamide (2-AB) labelled PNGase F released N-glycans has been proven to be 
reproducible and robust[25,27]. We used this method to analyse IgG glycosylation profiles of 
179individuals that were diagnosed with RA during 10-year follow-up after sampling (cases), 
and 358 matching controls that did not develop R in the same period. Herein we show that the 
IgG glycan aberrancy can be detected years before the onset of the disease and considered as a 
novel risk factor for RA.  
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2. Materials and Methods  
 
2.1.Study population. 
RA cases and controls were originally recruited to the FINRISK 2002 (N=8,595) and 2007 
(N=6,154) cohorts. FINRISK cohorts are population-based samples of Finns, described in more 
detail previously[28]. During the follow-up, 179 incident RA cases were identified among the 
study participants using the Finnish hospital discharge and causes of death registers with ICD-
codes: M05-M13, M32, M33, M45 (ICD-10) / 710, 714, 420, 725 (ICD-9) / 712, 734 (ICD-8) 
and the social insurance institution of Finland (KELA) special reimbursement for RA medication 
(KELA code 202). Two controls per case were frequency matched by gender, 5-year age group, 
FINRISK year and study region. Individuals who developed other autoimmune or chronic 
diseases were excluded from the present study. The median follow-up time was 4.31 years for 
cases (range 0.025 to 9.83 years) and 9.80 years for controls (range 0.33 to 9.94 years). 
 
2.2.IgG isolation, glycan release and labelling. 
The whole procedure was performed as previously reported[25]. Briefly, IgGs were isolated 
using Protein G 96-well plate (BIA Separations, Slovenia) from the serum samples. The isolated 
IgGs were denaturated with the addition of sodium dodecyl sulphate (SDS) (Invitrogen, USA) 
and by incubation at 65°C. The excess of SDS was neutralized with Igepal-CA630 (Sigma-
Aldrich, USA) and N-glycans were released following the addition of PNGase F (Promega, 
USA) in Phosphate Buffered Saline (PBS). The released N-glycans were labelled with 2-AB. 
Free label and reducing agentwere removed from the samples using hydrophilic interaction 
liquid chromatography solid-phase extraction (HILIC-SPE). Glycans were eluted with ultrapure 
water and stored at –20°C until use. 
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2.3.Ultra-performance liquid chromatography. 
Fluorescently labelled N-glycans were separated by HILIC on an Acquity UPLC instrument 
(Waters, USA) consisting of a quaternary solvent manager, sample manager, and an FLR 
fluorescence detector set with excitation and emission wavelengths of 250 and 428 nm, 
respectively. The instrument was under the control of Empower 3 software, build 3471 (Waters). 
Labelled N-glycans were separated on a Waters BEH Glycan chromatography column, 100 × 2.1 
mm i.d., 1.7 µm BEH particles, with 100 mM ammonium formate, pH 4.4, as solvent A and 
ACN as solvent B. The separation method used a linear gradient of 25-38% solvent A at flow 
rate of 0.40 ml/min in a 27 min analytical run. Samples were maintained at 10°C before 
injection, and the separation temperature was 60°C. Data processing was performed using an 
automatic processing method with a traditional integration algorithm, after which each 
chromatogram was manually corrected to maintain the same intervals of integration for all the 
samples. The chromatograms were all separated in the same manner into 24 peaks as previously 
reported[7]. The amount of glycans in each peak was expressed as % of total integrated area. 
Derived traits were calculated according the following formulas: for agalactosylated G0 = 
GP1+GP2+GP3+GP4+GP6, with one galactose G1 = GP7+GP8+GP9+GP10+GP11, with two 
galactoses G2 = GP12+GP13+GP14+GP15 and sialylated glycans S = 
GP16+GP17+GP18+GP19+GP21+GP22+GP23+GP24. 
 
2.4.Data analysis. 
The glycan variables were first inverse normal transformed and standardized to mean=0 and 
standard deviation=1. Then, for each of the transformed glycan variables, a linear regression 
model adjusted for sex, age, age group ([,30 y}, [30 y, 40 y}, [40 y, 55 y}, [55 y, 70 y}, [70 y, }), 
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and an age*sex interaction term was fitted and the residuals from the model were extracted. The 
association of the residuals with RA was then tested with incident disease (yes/no)using logistic 
regression and, in cases only, with time from sampling to diagnosis (years) using linear 
regression. To take into account multiple testing in the presence of substantial correlation 
between the glycan variables, principal component analysis was used. As the first 19 principal 
components explained more than 99% of the variance in the glycan residuals, the P-values for 
the logistic regression tests were adjusted by multiplying the nominal P-values by 19. P-values 
for tests with time to diagnosis as the dependent variable are presented without adjusting for 
multiple testing. 
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3. Results  
 
IgG N-glycans were released by PNGase F, labelled with 2-AB andanalysed by HILIC-UPLC. 
Obtained chromatograms were integrated into 24 peaks which mostly contained individual N-
glycans (Figure 1)[7]. The association of the N-glycanswith incident RA was tested using 
logistic regression (Table 2). 
 Glycan peaks GP3, GP4 and GP6were increased in RA cases when compared to controls 
(nominal P-value<0.05).These peakscontain agalactosylated glycan structures A2B, FA2 and 
FA2B, respectively. On the contrary, the proportion of total area comprised by the glycan peaks 
containing structures with one galactose (GP8 and GP9) or two galactoses (GP12, GP13, and 
GP14) was smaller in cases, as were the % areas of the peaks GP18 and GP23 containing 
sialylated IgG glycans (nominal P-value<0.05). The derived variables for agalactosylation (G0),  
monogalactosylation (G1), and digalactosylation (G2) were also nominally significant. The 
associations of the peak GP6 (agalactosylated glycan FA2B), total agalactosylation (G0), and 
total monogalactosylation (G1) with RA remained statistically significant after adjusting the P-
values for multiple testing (PGP6=0.008, PG0=0.027, PG1=0.029, Table 2). 
 The association oflow IgGgalactosylation with future diagnosis of RA may reflect 
changes occurring during early phase of the disease, or, alternatively, it may indicate that low 
IgG galactosylation is a pre-determined or acquired risk-factor. Aiming to distinguish between 
these two alternative hypotheses, we checked whether the observed changes associate with the 
time between sampling and RA diagnosis (Table 2, Figure 2). 
 The only variable showing a nominally significant association was GP9 that correlated 
with a lower risk of RA and a longer time between taking the blood sample and diagnosis with 
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RA, but neither of these associations remained statistically significant after adjusting the P-value 
for multiple testing. Noneof the N-glycan variables that robustly associated with RA risk (GP6, 
G0, and G1) correlated with the time between RA diagnosis and the date of participating in the 
study (Table 2, Figure 2).  
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4. Discussion 
 
Results of our study are in accordance with the previous studies that reported decreased 
galactosylation in RA [8,16,29]. The decreasein galactosylation and sialylationin RAhas been 
known for a long time[8] and was observed in multiple independent studies[16,29]. The decrease 
inIgG galactosylation has beenregularly associated with RA[8,10,15,30–36], while changes in 
sialylation were reported to be independent of galactosylation[9]and the decrease in sialylation 
wasfar less reported[8,10,15,37]. It is known that both anti-inflammatory and pro-inflammatory 
activities of IgGare determined by which Fcγ receptor they preferentially bind toand that the 
receptor affinity depends on the composition of the glycan linked to the 297 asparagine. IgG 
carrying G0 glycans hasincreased affinity to FcγRIII, an activating FcR, and the serum 
lectinmannose-binding protein[38,39]. Moreover, besides the classical and lectin pathways of 
complement activation, IgG bearing G0 is able to activate an alternative complement 
pathway[40].Such G0-bearing IgGsare thus uniquely capable of setting autoimmunity.To the 
contrary, higher sialylation of IgG decreases its affinity for FcγRIIIand increases the expression 
of FcγRIIB,an inhibitory FcR[38]. 
This is not the first study which reported that IgG glycosylation changes could be 
observed before the onset of symptoms[31,41,42], yet there is disagreement between studies 
about the time point when changes are starting to be visible. Ercan et al. concluded that the 
changes could be noticed at least 3.5 years[41] and Young at al. observed them two years prior 
the onset of symptoms[31], while Rombouts et al. stated that a decrease in galactose residues 
occurred around three months prior to diagnosis and only in ACPA-IgG[42]. In this study we 
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detected robust association of low IgG galactosylation (andnominally significant association of 
low IgG sialylation)and risk for RA diagnosis during 10 years of follow-up.In our data, the 
median time from donating the blood sample used for glycan measurement to the subsequent 
diagnosis with RA was 4.31 years, ranging from less than two weeks to nearly ten years. Despite 
the wide time range we did not observe any statistically significant correlation between IgG 
glycosylation and the time from sampling to diagnosis, indicating that the decreased 
galactosylation is a pre-existing risk factor involved in the disease development. 
Low IgG galactosylation might be genetically pre-determined, or it might be acquired 
through the action of environmental factors. The heritability of RA is estimated to be some 40-
65% and 20% for seropositive and seronegative arthritis, respectively[2]. The heritability of IgG 
N-glycomecomposition is also known to be relatively high[7].Yarwood et al. recently looked for 
shared genetic factors between RA and IgG N-glycome using IgG N-glycosylation associated 
single nucleotide polymorphisms (SNPs) and found no association between them and risk for 
RA[24].This suggests low IgGgalactosylation may not be a genetically pre-determined risk 
factor. The differences in IgG N-glycans between RA cases and healthy controls precede 
diagnosis for years, which coincides with the preclinical period of the disease known as pre-
rheumatoid arthritis (pre-RA). This period includes a period in the RA development where 
genetics and environmental factors interact and which is followed by development of disease-
related autoantibodies and symptoms without clinical evidence of RA[43–45]. All these stages 
can be present years before RA establishment. Knowing that environmental risk factors such as 
smoking, obesity, periodontitis, hormones, diary and infections together with genetic risk factors 
play an important role in the first stage of pre-RA[44], and some of these factors are known to 
affect the IgG glycome [7,46].Therefore, this indicates that stable long-acting factors affecting 
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IgG glycome composition are among of the underlying mechanism of RA and makes IgG 
glycosylation a novel risk factor for RA which should be considered for risk estimation of 
RA[47]. Moreover, knowing that IgG N-glycans are affecting inflammatory activity of IgG, this 
may be an indication that the glycans are not only a biomarker but a functional effector of the 
disease.. 
As joint destruction increases with disease progression, new biomarkers should be found 
to establish the diagnosis early to reduce or prevent consequent damage[2]. Today, the diagnosis 
is primarily based on serological testing for RFs and ACPAs[16], and they are known to be 
present in serum long before the onset of the disease[48].However, the aforementioned 
biomarkers are neither detectable in every RA patient (merely 70%) nor are selective for RA 
since they could also result from other diseases[16]. Therefore, IgGglycans have a considerable 
potential to be a biomarker of the disease; since they have been shown to have, combined with 
RF titters, a positive predictive value of 94% for RA diagnosis[31]. Moreover, 
agalactosylatedIgG levels are known to correlate with the disease remission, progression and 
successful therapy treatment[16]. Indeed, IgGglycans follow a temporary improvement of RA 
during pregnancy by an increase in IgGgalactosylation and sialylation as well as a decrease of 
the same glycan traits after delivery, which correlates with a postpartum relapse[10]; those 
changes could be attributed to higher estrogen levels in pregnancy which is known to modulate 
IgGgalactosylation[49].  
Even though the method applied in this study for IgG N-glycome analysis,as well as 
other analytical techniques which require HPLC/UPLC and mass spectrometry, are not yet 
routinely used in the clinic for disease diagnostic, undergalactosylatedIgG could be easily 
estimated by ELISA techniques using protein G in combination with 
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biotinylatedPsathyrellavelutinalectin (PVL), which preferentially interacts with the N-
acetylglucosaminegroup exposed at the termini of sugar chains in agalactosylatedIgG. Moreover, 
the assay was able to distinguish RA from other autoimmune diseases[23]. 
In conclusion, in this study we showed that IgG N-glycosylationcorrelates with RA years 
before RA diagnosis and indicates an active involvement of N-glycans in the disease pathology. 
Moreover, these early changes ofIgG N-glycome may thus be useful in constructing a sensitive 
and specific test for early RA diagnosis, needed to enable prompt treatment and prevent 
irreversible joint destruction as well as to evaluate disease progression, remission and proper 
treatment.  
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Figure legends 
Figure 1. Representative chromatogram of 2-AB labelled N-linked glycans released from IgGs 
isolated from human serum and separated by HILIC-UPLC. The integration areas, together with 
a major structure presented in each glycan peak are given. Glycan peaks are numbered from 
GP1-GP24, as used in the paper. 
 
Figure 2. Agalactosylation of IgG and time from sampling to diagnosis with rheumatoid arthritis 
in cases only. Residual G0 is independent of the time from recruitment to diagnosis in cases. The 
derived agalactosylation variable G0 was formed by summing the peaks GP1, GP2, GP3, GP4, 
and GP6. It was then inverse normal transformed and a linear regression model adjusted for 
cohort, age, sex, age*sex interaction term, and age group ([,30}, [30, 40}, [40, 55}, [55, 70}, [70, 
}) was fitted to the transformed variable and residuals from that model were extracted. The dots 
represent individual measurements while the box plots summarize data from individuals across 
the four groups of [0.0, 2.5}, [2.5, 5.0}, [5.0, 7.5}, and [7.5-10} years. 
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Table 1. Age and sex distribution of the study sample. 
Age group Control men Control women Case men Case women 
(,30] 6 (1.7 %) 8 (2.2 %) 3 (1.7 %) 4 (2.2 %) 
(30,40] 14 (3.9 %) 28 (7.8 %) 7 (3.9 %) 14 (7.8 %) 
(40,55] 34 (9.5 %) 88 (24.6 %) 17 (9.5 %) 44 (24.6 %) 
(55,70] 76 (21.2 %) 68 (19 %) 38 (21.2 %) 34 (19 %) 
(70, ] 16 (4.5 %) 20 (5.6 %) 8 (4.5 %) 10 (5.6 %) 
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Table 2.Association of rheumatoid arthritis and IgG N-glycome. 
Glycan 
trait OR (95% CI)* P (OR)* Padjusted (OR)* Beta (95% CI)** P (beta)** 
S 0.82 (0.66 to 1) 0.064 1 -0.2 (-0.64 to 0.24) 0.38 
G0 1.5 (1.2 to 1.9) 0.0014 0.027 -0.0034 (-0.5 to 0.49) 0.99 
G1 0.74 (0.61 to 0.89) 0.0015 0.029 0.4 (-0.012 to 0.81) 0.059 
G2 0.71 (0.56 to 0.91) 0.007 0.13 0.00033 (-0.49 to 0.49) 1 
GP1 1.2 (0.98 to 1.5) 0.083 1 -0.18 (-0.63 to 0.26) 0.43 
GP2 1 (0.86 to 1.3) 0.67 1 -0.094 (-0.5 to 0.31) 0.65 
GP3 1.2 (1 to 1.5) 0.036 0.68 0.21 (-0.21 to 0.63) 0.32 
GP4 1.4 (1.1 to 1.8) 0.0045 0.085 0.037 (-0.44 to 0.52) 0.88 
GP5 1.1 (0.94 to 1.4) 0.2 1 -0.018 (-0.43 to 0.39) 0.93 
GP6 1.5 (1.2 to 1.9) 0.00042 0.008 -0.17 (-0.66 to 0.32) 0.5 
GP7 0.85 (0.7 to 1) 0.074 1 -0.082 (-0.46 to 0.3) 0.67 
GP8 0.77 (0.63 to 0.93) 0.0063 0.12 0.35 (-0.057 to 0.76) 0.094 
GP9 0.81 (0.67 to 0.97) 0.026 0.49 0.41 (0.018 to 0.8) 0.042 
GP10 1.2 (0.96 to 1.4) 0.13 1 -0.22 (-0.64 to 0.2) 0.31 
GP11 1.2 (0.99 to 1.5) 0.061 1 -0.15 (-0.57 to 0.27) 0.49 
GP12 0.78 (0.64 to 0.95) 0.013 0.25 -0.19 (-0.61 to 0.22) 0.36 
GP13 0.83 (0.68 to 1) 0.045 0.86 -0.019 (-0.41 to 0.37) 0.92 
GP14 0.71 (0.56 to 0.92) 0.008 0.15 0.057 (-0.45 to 0.56) 0.83 
GP15 0.92 (0.75 to 1.1) 0.42 1 -0.26 (-0.66 to 0.15) 0.22 
GP16 0.99 (0.83 to 1.2) 0.93 1 0.17 (-0.22 to 0.55) 0.4 
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GP17 0.91 (0.75 to 1.1) 0.33 1 -0.36 (-0.77 to 0.044) 0.082 
GP18 0.77 (0.61 to 0.97) 0.029 0.56 -0.19 (-0.67 to 0.29) 0.44 
GP19 1 (0.83 to 1.2) 0.99 1 -0.18 (-0.56 to 0.19) 0.34 
GP20 0.92 (0.77 to 1.1) 0.41 1 0.19 (-0.18 to 0.56) 0.32 
GP21 0.87 (0.72 to 1) 0.14 1 -0.017 (-0.4 to 0.37) 0.93 
GP22 0.96 (0.8 to 1.2) 0.69 1 -0.19 (-0.58 to 0.2) 0.35 
GP23 0.79 (0.65 to 0.96) 0.019 0.37 -0.0036 (-0.41 to 0.4) 0.99 
GP24 1 (0.84 to 1.2) 0.98 1 -0.26 (-0.65 to 0.12) 0.18 
Glycan variables were first inverse normal transformed and a linear regression model adjusted for cohort, age, sex, 
age*sex interaction term, and age group ([,30}, [30, 40}, [40, 55}, [55, 70}, [70, }) was fitted for each glycan. 
Residuals from these models were extracted and used to test for association with rheumatoid arthritis (yes/no) using 
logistic regression and with time to diagnosis from sampling (cases only) using linear regression. P-values for tests 
with rheumatoid arthritis (yes/no) were adjusted for multiple testing by multiplying them by 19. P-values for tests 
with time to diagnosis from sampling as the dependent variable are presented without adjusting for multiple testing. 
OR - odds ratio, CI - confidence interval, GP  - glycan peak, G0 – agalactosylated N-glycans, G1 – N-glycans with 
one galactose, G2 – N-glycans with two galactoses, S – sialylated N-glycans.  
* Logistic regression for rheumatoid arthritis (yes/no) 
** Linear regression for time from sampling to diagnosis with rheumatoid arthritis (years). 
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Highlights 
 Future diagnosis of rheumatoid arthritis is associated with lower galactosylation of IgG  
 IgG glycosylation alterations are present years before diagnosis  
 Glycosylation is a pre-existing risk factor involved in the disease development 
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